Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases

J Crohns Colitis. 2011 Oct;5(5):457-60. doi: 10.1016/j.crohns.2011.03.014. Epub 2011 May 6.

Abstract

We report two cases of Stevens-Johnson syndrome (SJS) associated with the use of sulfasalazine in two ulcerative colitis patients previously tolerant to mesalamine. SJS and toxic epidermal necrolysis (TEN) are very rare adverse cutaneous reactions that can be associated with the use of sulfasalazine. The most severe cases can result in death, and for the others, permanent skin, mucosal or ocular sequelae, which can impair the quality of life in our young IBD patients. Clinicians and patients need to be aware of the signs and symptoms that often precede the appearance of the mucocutaneous lesions in a SJS or TEN, such as fever, influenza-like symptoms, sore throat or burning eyes. For patients with SJS or TEN, immediate withdrawal of the offending medication should be done when blisters or erosions appear in the course of a drug eruption, as this may improve the prognosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Colitis, Ulcerative / drug therapy*
  • Female
  • Humans
  • Stevens-Johnson Syndrome / diagnosis
  • Stevens-Johnson Syndrome / etiology*
  • Sulfasalazine / adverse effects*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Sulfasalazine